2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

2:30PM-4:00PM: Abstract Number: 2807

Association of Exposure to Childhood Abuse with Incident Systemic Lupus Erythematosus in a Longitudinal Cohort of Women

5T086 ACR Abstract: Epidemiology & Pub Health III: SLE & SSc, Big Data & Large Cohorts (2802–2807)

2:30PM-4:00PM: Abstract Number: 2847

Associations between Serum Uric Acid Level and Coronary Artery Disease

5T099 ARHP Abstract: Clinical Aspects & Outcomes Research–ARHP II (2844–2849)

2:30PM-4:00PM: Abstract Number: 2817

Cardiovascular Disease Risk with Biologics and Tofacitinib Compared to Conventional Synthetic Dmards in Patients with Rheumatoid Arthritis

5T088 ACR Abstract: RA–DX, Manifestations, & Outcomes IV: CV Co-Morbidities (2814–2819)

2:30PM-4:00PM: Abstract Number: 2815

Cardiovascular Safety – Update from up to 6 Years of Treatment with Baricitinib in Rheumatoid Arthritis Clinical Trials

5T088 ACR Abstract: RA–DX, Manifestations, & Outcomes IV: CV Co-Morbidities (2814–2819)

2:30PM-4:00PM: Abstract Number: 2791

Characterization of Monoclonal Anti-PAD4 Autoantibodies from Rheumatoid Arthritis Patients: Functional Implications for Citrullination and Disease Progression

5T085 ACR Abstract: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (2791–2796)

2:30PM-4:00PM: Abstract Number: 2806

Childhood Physical and Sexual Abuse and Risk of Systemic Lupus Erythematosus Among African American Women

5T086 ACR Abstract: Epidemiology & Pub Health III: SLE & SSc, Big Data & Large Cohorts (2802–2807)

2:30PM-4:00PM: Abstract Number: 2838

Comorbid Vasculitis Among Patients in a National Primary Immunodeficiency Database

5T093 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os II: Novel Diagnostics & THRs (2838–2843)

2:30PM-4:00PM: Abstract Number: 2823

Comparative Long-Term Effectiveness of Switching to Another Tumour Necrosis Factor Antagonists, Tocilizumab or Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to a First-Line TNF Inhibitor

5T089 ACR Abstract: RA–Treatments IV: Strategy (2820–2825)

2:30PM-4:00PM: Abstract Number: 2833

Complement Activation Is a Feature of Diseases in the Lupus Spectrum

5T090 ACR Abstract: SLE–Clinical III: Translational Aspects (2832–2837)

2:30PM-4:00PM: Abstract Number: 2816

Development of a Microrna Panel for Predicting Coronary Atherosclerosis in Rheumatoid Arthritis

5T088 ACR Abstract: RA–DX, Manifestations, & Outcomes IV: CV Co-Morbidities (2814–2819)

2:30PM-4:00PM: Abstract Number: 2837

Diminished STAT-3 Phosphorylation and Associated Cell Pathways Characterize MMF-Treated Systemic Lupus Erythematosus Patients

5T090 ACR Abstract: SLE–Clinical III: Translational Aspects (2832–2837)

2:30PM-4:00PM: Abstract Number: 2842

Does Leflunomide Have a Role in Giant Cell Arteritis?

5T093 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os II: Novel Diagnostics & THRs (2838–2843)

2:30PM-4:00PM: Abstract Number: 2821

Dose Tapering and Discontinuation of Biological Therapy in Rheumatoid Arthritis Patients in Routine Care – 2-Year Outcomes and Predictors

5T089 ACR Abstract: RA–Treatments IV: Strategy (2820–2825)

2:30PM-4:00PM: Abstract Number: 2826

Emergence of Severe Spondyloarthropathy Related Entheseal Pathology Following Successful Vedolizumab Therapy for Inflammatory Bowel Disease

5T091 ACR Abstract: Spondyloarthritis Incl PsA–Clinical IV: Comorbid/Related Conditions(2826–2831)

2:30PM-4:00PM: Abstract Number: 2812

Evaluation of Cortical Microarchitecture, Bone Stiffness and Bone Remodeling in Patients with Atypical Femoral Fracture

5T087 ACR Abstract: Osteoporosis & Metabolic Bone Disease–Basic & Clinical Science (2808–2813)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].